Factor V Leiden Mutation, DNA

What Factor V Leiden Mutation, DNA actually measures — the analyte, and the assay

The variant removes a pair of scissors' target, not a protein. Factor V Leiden is a single base change in F5 that replaces the arginine at position 506 with glutamine. Arginine 506 is one of three places activated protein C cuts activated factor V to shut clotting down. Take that site away and one of the three brakes stops working, so activated factor V lingers. The phenotype has a name of its own — activated protein C resistance — and it is measurable without touching DNA.

Which gives two tests with two failure modes. The genotype is a polymerase chain reaction looking for one letter. The functional assay is a clotting time run twice, once with added activated protein C and once without, reported as the ratio between them: a resistant plasma barely slows down when the brake is added, so its ratio is low.

The functional assay was fixed once, and knowing which version ran matters. First-generation activated protein C resistance was a plain modified aPTT and it responded to almost anything that changed clotting. Second-generation assays dilute the patient's plasma heavily into factor V-deficient plasma first, so the only factor V in the reaction is yours and the rest of the coagulation system is supplied by the reagent. That predilution is what made the test specific, and the practicalities of running and interpreting it have been set out in detail Kadauke 2014.

The site's own product for this marker is the DNA test, which sidesteps the entire interference discussion below — at the cost of only ever answering one question.

Factor V Leiden Mutation, DNA: what changes the blood, and what only changes the reading

What changes the analyte in your body: nothing. That sentence is not a shortcut. A germline single-nucleotide variant is fixed at conception and identical in every nucleated cell. No drug, diet, illness or training block alters it, and no result on this page can be improved.

What changes the functional phenotype — the activated protein C resistance ratio, in someone who does not carry the variant:

1. Pregnancy, which produces acquired resistance through rising factor VIII and falling free protein S, and does it progressively across gestation.
2. Estrogen exposure, including combined oral contraceptives and menopausal hormone therapy, which shift the same balance in the same direction.
3. An acute-phase response, which raises factor VIII sharply and can pull a ratio down for weeks after an illness.
4. Other F5 variants entirely, which produce resistance by other routes and which a targeted genotype assay reports as negative.

What changes only the reading:

1. Any anticoagulant present when the blood was drawn. Heparin, vitamin K antagonists and the direct oral anticoagulants all act on the reaction the assay is timing, and the direct agents in particular distort clot-based testing in a dose- and timing-dependent way Moser 2021.
2. A lupus anticoagulant, whose effect on activated protein C resistance testing has been examined specifically to ask whether it is an in vitro phenomenon or a real physiological one Shen 2011. Either way the ratio it produces is not factor V Leiden.
3. Which generation of the functional assay ran. A first-generation ratio and a second-generation ratio on the same plasma are different numbers with different specificities Kadauke 2014.
4. A short-filled citrate tube, which over-anticoagulates the sample before it reaches the analyzer.
5. On the genotype: nothing whatsoever. There is no interference, no drug effect and no pre-analytical variable. A genotype that reads differently on a second sample means the two samples were not from the same person.

Reference interval or decision threshold — which kind of number Factor V Leiden Mutation, DNA is

The genotype has no range; it has a penetrance. Negative, heterozygous and homozygous are categories, and the number that actually informs anybody is how often carriers have events — which is a probability, not a boundary.

The functional ratio does have a cut-off, and it is a decision threshold set against the genotype. Each laboratory establishes the ratio below which it will call a sample resistant, by running samples of known genotype. It is a method-specific operating point, not a biological line Kadauke 2014.

Here is the penetrance, in the form that matters — absolute risk, and how exposure multiplies it. Across three thrombophilia strata, venous thromboembolism ran at 0.13, 0.35 and 0.94 per 100 woman-years overall. During combined oral contraceptive use the same strata ran 0.19, 0.49 and 0.86. During pregnancy they ran 0.73, 1.97 and 7.65 van Vlijmen 2011. Even in the highest stratum during pregnancy, roughly 92 women in 100 pass through a year without an event.

The relative numbers look far more dramatic than the absolute ones, which is exactly why both belong on the page. In the study that first quantified the interaction, oral contraceptive users had 3.8 times the thrombosis risk (95% CI 2.4 to 6.0), carriers of the variant 7.9 times (3.2 to 19.4), and women with both more than 30 times — 34.7, with a confidence interval running from 7.8 to 154 Vandenbroucke 1994. A confidence interval spanning a twentyfold width is telling you how few events built it.

How you would know your Factor V Leiden Mutation, DNA was wrong — and when to redraw

Never, for the genotype. This is one of two markers in the estate with a genuinely permanent answer, and a second test is only ever justified to disprove a suspected sample mix-up.

The functional assay, by contrast, has strict conditions and is worth repeating when they were not met: off heparin and off direct oral anticoagulants for at least two to three elimination half-lives Moser 2021; not during pregnancy and not within about six weeks of delivery; ideally off estrogen; and clear of an acute illness by several weeks.

How you would know a functional result was wrong:

• Order the genotype. It is the reference standard the functional cut-off was calibrated against, and it settles the question permanently Kadauke 2014.
• If the genotype is negative and the ratio is still low, the resistance is acquired — pregnancy, estrogen, factor VIII or a lupus anticoagulant Shen 2011 — and that is a different finding requiring different follow-up.
• Ask what medication was in the blood. A resistant ratio in an anticoagulated sample is an assay artifact until repeated off drug.
• Do not use D-Dimer or Fibrinogen to confirm this. Neither speaks to activated protein C resistance; they answer different questions and a normal value in either excludes nothing.

What Factor V Leiden Mutation, DNA cannot tell you

It cannot tell you that you will have a clot, and for most carriers it never happens. The absolute figures above are the honest scale of it van Vlijmen 2011. What this result changes is the conversation about specific exposures — contraception, pregnancy, long-haul travel, surgery — and that conversation belongs with a clinician who knows the family history.

It cannot be read without the exposure beside it. In one case-control series, factor V Leiden appeared in 12.2% of patients and 1.6% of controls, with an odds ratio of 5.2 (95% CI 1.4 to 19.5) that rose to 14.3 (3.3 to 64.6) among oral contraceptive users Aznar 2000. The variant and the exposure multiply; neither number means much alone.

It says nothing about arterial disease. Factor V Leiden is a venous story. Heart attack and stroke risk are addressed by ApoB, Lp(a) and blood pressure, and a negative result here provides no reassurance about any of them.

A negative genotype does not exclude activated protein C resistance. The assay looks for one letter; other F5 variants and the acquired causes above produce the phenotype without it Kadauke 2014 Shen 2011.

The wrong inference readers actually draw is that a heterozygous result is a diagnosis requiring lifelong treatment. It is a risk modifier whose absolute effect, in the absence of an exposure, is measured in fractions of a percent per year van Vlijmen 2011.

Sources read for these sections

• Kadauke S, et al. Activated protein C resistance testing for factor V Leiden. American Journal of Hematology 2014 · PMID 25293789
• Shen YM, et al. Lupus anticoagulant interference in activated protein C resistance testing: in vitro phenomenon or in vivo pathophysiologic effect?. Clinical and Applied Thrombosis/Hemostasis 2011 · PMID 21406411
• Vandenbroucke JP, et al. Increased risk of venous thrombosis in oral-contraceptive users who are carriers of factor V Leiden mutation. Lancet 1994 · PMID 7968118
• van Vlijmen EF, et al. Thrombotic risk during oral contraceptive use and pregnancy in women with factor V Leiden or prothrombin mutation: a rational approach to contraception. Blood 2011 · PMID 21659542
• Aznar J, et al. Risk of venous thrombosis in carriers of the prothrombin G20210A variant and factor V Leiden and their interaction with oral contraceptives. Haematologica 2000 · PMID 11114134
• Moser KA, et al. Direct oral anticoagulant (DOAC) interference in hemostasis assays. Hematology, American Society of Hematology Education Program 2021 · PMID 34889400